pepmg_

Study summary · research use only

Fluorous oligoarginines as supra-enhancers for intracellular and transdermal peptide delivery

Study · Bioactive materials · 2026 · DOI 10.1016/j.bioactmat.2025.12.027 · PMID 41551769

Plain-language summary

Paraphrased from the published abstract below — not a verdict on whether anything works.

In this study (species not specified; cell, 3D tumor spheroid, and skin models), the authors developed a library of fluorous penetrating peptides and identified fluorinated hexa-arginine (FR6). FR6 was reported to enhance intracellular delivery of various peptides by increasing membrane permeability and uptake across cell types, and to improve peptide penetration in 3D tumor spheroids. FR6 was also reported to enhance transdermal delivery of peptide drugs, including acetyl hexapeptide-8, for UVB-induced skin photoaging. The authors describe FR6 as a candidate enhancer for overcoming cell, tissue, and transdermal delivery barriers for peptides.

Abstract

Peptides are increasingly recognized as important therapeutics due to their specificity and potency. However, their clinical application is often hindered by numerous barriers, including low bioavailability, poor cell membrane and tissue penetration. To address these limitations, we developed a library of fluorous penetrating peptides and identified fluorinated hexa-arginine (FR6) as a super-enhancer for cell and tissue penetration. FR6 markedly enhances the intracellular delivery of a variety of peptides by improving membrane permeability, facilitating their uptake across diverse cell types. It greatly improves the penetration of bioactive peptides in 3D tumor spheroids, allowing for improved therapeutic efficacy. More importantly, FR6 demonstrates remarkable potential for transdermal delivery of peptide drugs, effectively enhancing the penetration of peptides like acetyl hexapeptide-8 for treating UVB-induced skin photoaging. Our findings underscore the use of FR6 as a super-enhancer in overcoming multiple physiological barriers during cell, tissue and transdermal delivery.

Read the full study on PubMed ↗ Open-access full text ↗

pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.